| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 50.921 | 15.935 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Total Income - EUR | 51.122 | 15.935 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Total Expenses - EUR | 60.445 | 12.078 | 1.672 | 165 | 0 | 0 | 0 | - | - | - |
| Gross Profit/Loss - EUR | -9.323 | 3.857 | -1.672 | -165 | 0 | 0 | 0 | - | - | - |
| Net Profit/Loss - EUR | -10.877 | 3.538 | -1.672 | -165 | 0 | 0 | 0 | - | - | - |
| Employees | 1 | 1 | 1 | 0 | 0 | 0 | 0 | - | - | - |
Check the financial reports for the company - Mezopharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 3.263 | 3.059 | 2.840 | 2.623 | 2.572 | 2.523 | 2.467 | - | - | - |
| Current Assets | 33.917 | 36.027 | 34.313 | 33.683 | 33.031 | 32.405 | 31.925 | - | - | - |
| Inventories | 21.572 | 22.495 | 22.114 | 21.708 | 21.288 | 20.884 | 20.421 | - | - | - |
| Receivables | 9.695 | 9.594 | 9.431 | 9.258 | 9.079 | 8.907 | 8.949 | - | - | - |
| Cash | 2.650 | 3.938 | 2.767 | 2.717 | 2.664 | 2.614 | 2.556 | - | - | - |
| Shareholders Funds | -8.489 | -4.855 | -6.445 | -6.492 | -6.366 | -6.245 | -6.107 | - | - | - |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | - | - | - |
| Debts | 45.804 | 44.075 | 43.729 | 42.927 | 42.096 | 41.297 | 40.621 | - | - | - |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Mezopharma S.r.l.